Impact on Patient Care

Home > Impact on Patient Care

Biosimilars reach patients in two ways: hospital use, in most cases, and via medical prescription. They are used to treat serious illnesses, often chronic, in the areas of dermatology, rheumatology, gastroenterology, oncology, neurology, and ophthalmology, among others.

For patients who want further information on biosimilars, the European Commission has drafted an informative flyer with the European Medicines Agency (EMA), the European Patients’ Forum (EPF), the Standing Committee of European Doctors (CPME), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Association for Bioindustries (EuropaBio).

In this document, experts state that biosimilar drugs are subjected to intensive evaluation prior to marketing to ensure that their safety and efficacy is the same as that of the original drug.